Nociceptin/orphanin FQ (N/OFQ), nocistatin, and prepro-N/OFQ 160 -187 (C-peptide) are all derived from the same precursor protein. We examine the pharmacological mechanisms of nocistatin-and C-peptide-induced pronociceptive responses in a novel algogenic-induced nociceptive flexion test in mice. The intraplantar (i.pl.) injection of nocistatin-and C-peptide induced pronociceptive responses in a range of 0.01 to 10 or 1 pmol, respectively, which showed 100-to 1000-fold less potent effects than the N/OFQ. The nociceptive effects of both peptides were not affected by 1-[(3R,4R)-1-cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one (J-113397) (i.pl.), an N/OFQ receptor antagonist, indicating that they are mediated by a novel mechanism independent of activation of N/OFQ receptor. Like N/OFQ, nocistatin-induced nociception was abolished by i.pl. injection of pertussis toxin, phospholipase C inhibitor, or CP-99994, a neurokinin 1 receptor antagonist, indicating that nocistatin may elicit nociception through a substance P release from nociceptor endings via activation of G i/o and phospholipase C. The nociception was abolished by neonatal pretreatment (s.c.) with capsaicin or by i.t. pretreatment with CP-99994, but not , an N-methyl-D-aspartate receptor antagonist. In contrast, C-peptide-induced nociception was attenuated by the pretreatment with antisense oligodeoxynucleotide for G␣ s (i.t.) and with KT-5720 (i.pl.), a cyclic AMP-dependent protein kinase inhibitor, but not with pertussis toxin. The nociception was neither attenuated by neonatal capsaicin nor by i.t. injection with CP-99994, but it was attenuated by i.t. injection with MK-801. These results suggest that nocistatin and C-peptide derived from prepro-N/OFQ stimulate distinct nociceptive fibers through different in vivo signaling mechanisms.
Nociceptin/orphanin FQ (N/OFQ), discovered as the endogenous peptide ligand for N/OFQ receptor/NOP (Meunier et al., 1995; Reinscheid et al., 1995) , is generated from a larger precursor protein, prepro-N/OFQ (Saito et al., 1995; Mollereau et al., 1996; Nothacker et al., 1996) . N/OFQ has been seen as active at multiple sites of nociceptive transmission, ranging from peripheral nociceptors (Inoue et al., 1998) to nociceptive centers in the brain (Morgan et al., 1997) . Pharmacologically, the actions of N/OFQ are complex and seem to be contradictory; intracerebroventricular or intrathecal (i.t.) administration of this peptide exerts pronociceptive (or hyperalgesia) and/or analgesia (for reviews, see Calo, 2000; Mogil and Pasternak, 2001) . We also previously reported that N/OFQ (i.t.) exerts nocifensive actions in a femtomolar dose range through a substance P release from primary substance P fibers, whereas analgesic actions in a nanomolar dose range come through an inhibition of substance P actions on the second-order neuron in the spinal cord (Inoue et al., 1999) . These findings suggest that the opposing actions of N/OFQ may depend on the dose administered.
However, nocistatin, another peptide derived from the same precursor protein, has been shown to be an anti-N/OFQ peptide that diminished N/OFQ-induced allodynia and hyperalgesia (Okuda-Ashitaka et al., 1998) . In addition, several lines of evidence suggest that nocistatin is a biologically active peptide involved in nociception at the spinal level (Xu et al., 1999; Okuda-Ashitaka and Ito, 2000; Zeilhofer et al., 2000) . Prepro-N/OFQ (160 -187), which is the C-terminal peptide derived from the same prohormone (C-peptide), has been identified in the brain and the spinal cord Mathis et al., 2001) . Because administration of this peptide into brain regions produces antinociception or pronociceptive actions (Mathis et al., 2001; Rossi et al., 2002) , this peptide is also a biologically active peptide, probably activating a membrane receptor that has yet to be identified. Little is known, however, of the in vivo signal transduction of these peptides derived from the N/OFQ precursor in pain control.
Recently, we developed a new technique in mice to study the mechanism of pronociceptive actions induced by intraplantar injection of various algogenics (Inoue et al., 1998; Ueda 1999) . We called it algogenic-induced nociceptive flexion (ANF) test. This test has been proved to be advantageous in the point of sensitivity, compared with the known test measuring biting and licking behaviors, which we called algogenic-induced biting and licking test (Inoue et al., 2003b) . The ANF test was about 10,000 times more sensitive to produce nociception by various algogenics than the algogenicinduced biting and licking test (Inoue et al., 2003b) . Because constant nociceptive flexor responses upon repeated challenges of algogenics are observed, the ANF test is useful to characterize the dose-response relationship and in vivo signaling of nociception (Inoue et al., 1998; Ueda 1999) . Furthermore, we found very little increase in plasma corticosterone levels after the ANF test in the absence and presence of bradykinin stimulation (40% of control level), which is equivalent to those in mild nociception tests such as Hargreaves thermal and paw pressure mechanical tests (Inoue et al., 2003b) . Considering the fact that significant increase in plasma corticosterone levels was observed after both formalin and tail-flick tests (150% of control level), the ANF test is unlikely accompanied with heavy stress. Using this ANF test, we have studied pharmacological mechanisms of pronociceptive and antinociceptive actions of N/OFQ and N/OFQ (13) (14) (15) (16) (17) , an N/OFQ C-terminal fragment, and revealed that these peptides stimulate G i/o , phospholipase C and substance P release from nociceptor endings (Inoue et al., 1998 (Inoue et al., , 1999 (Inoue et al., , 2001 . Here, we report the pharmacological mechanisms underlying nocistatin-or C-peptide-induced pronociceptive actions using the ANF test.
Materials and Methods

Animals.
Male ddY mice weighing 20 to 22 g were used. They were kept in a room maintained at 21 Ϯ 2°C with free access to a standard laboratory diet and tap water. Procedures were approved by Nagasaki University Animal Care Committee and complied with the recommendations of the International Association for the Study of Pain (Zimmermann et al., 1983) .
Drugs. The following drugs were used: N/OFQ (Sawady Technology, Tokyo, Japan), nocistatin (Peptide Institute, Osaka, Japan), capsaicin (Nacalai Tesque, Kyoto, Japan), MK-801 (Sigma/RBI, Natick, MA), pertussis toxin (Funakoshi, Tokyo, Japan), and KT-5720 and calphostin C (Wako Pure Chemicals, Tokyo, Japan). Prepro-N/OFQ 160 -187 (C-peptide) was synthesized at Phoenix Pharmaceuticals Inc. (Belmont, CA). CP-99994 was generously provided by Pfizer Pharmaceuticals (Sandwich, Kent, UK). 1-[(3R,4R)-1-Cyclooctylmethyl-3-hydroxymethyl-4-piperidyl]-3-ethyl-1,3-dihydro-2H-benzimidazole-2-one (J-113397) was generously provided by Banyu (Tokyo, Japan). All drugs except KT-5720, calphostin C, and capsaicin were dissolved in physiological saline. KT-5720 and calphostin C were dissolved in 30% dimethyl sulfoxide, capsaicin in 10% ethanol, and 10% Tween 80 in physiological saline.
Treatment of Antisense Oligodeoxynucleotide (AS-ODN).
The AS-ODN (5Ј-AGT CAC CCA TTA GTG ACG CC-3Ј) and its missense oligodeoxynucleotide/MS-ODN (5Ј-AGC TAC CAC TAT GTG CAG CC-3Ј) for G␣ s were synthesized by Sawady (Tokyo, Japan), freshly dissolved in physiological saline, and used for i.t. injection in a volume of 2 l on the 1st, 3rd, and 5th days. On the 6th day, mice were used to assess the nocistatin-or C-peptide-induced nociception.
Western Blot Analysis. To confirm the effect of AS-ODN for G␣ s , SDS-polyacrylamide gel electrophoresis using 12% polyacrylamide gel, and immunoblot analysis were performed as described previously . After three times treatments of AS-ODN on the 1st, 3rd, and 5th days, we isolated dorsal root ganglion on the 6th day. Ten micrograms of protein extracted from the dorsal root ganglion was used. To get equal transfer efficiency, we applied all samples to the same gel and carried out the immunoblot transfer using the same membrane. Visualization of immunoreactive bands was performed by use of an enhanced chemiluminescent substrate for detection of horseradish peroxidase, Super Signaling Substrate (Pierce Chemical, Rockford, IL). The intensities of the immunoreactive bands were analyzed by NIH Image for Macintosh after scanning exposed films.
ANF Test. Experiments were performed, as described previously (Inoue et al., 1998; Ueda, 1999) . Briefly, mice were held in a cloth sling with their four limbs hanging free through holes. The sling was suspended on a metal bar. All limbs were tied with strings, and three were fixed to the floor, whereas the other one was connected to an isotonic transducer and recorder. A polyethylene cannula (0.61 mm in outer diameter) filled with drug solution was connected to microsyringe and then carefully inserted into the undersurface of the right hind paw. We used light, soft polyethylene cannulae to ensure that they did not fall off the paw during the experiments. As the intensity of flexor responses differs from mouse to mouse, we used the biggest response among spontaneous and nonspecific flexor responses occurring immediately after cannulation as the maximal reflex. Algogenic substance injection was given intraplantarly (i.pl.) every 5 min unless otherwise stated. Algogenic substance-induced nociceptive activity was expressed as the ratio of the maximal reflex in each mouse, and in the dose-response experiments, increasing doses of compound were given every 5-min interval. Averages of responses by twice-repeated challenges per each dose were evaluated. In some experiments, nocistatin (or C-peptide)-induced nociceptive activity was expressed as the ratio of the response observed over the average of twice-repeated control nocistatin (or C-peptide)-induced responses obtained at the beginning of the experiments. Test drugs affecting nocistatin (or C-peptide) responses were given through another cannula immediately after the second control response was measured. Intrathecal pretreatment with neurokinin 1 or NMDA receptor antagonist was performed 20 min before the nocistatin (or C-peptide) challenge.
Statistical Analysis. The data were analyzed using Student's t test. For the experiments with repeated injection of drugs in escalating doses, the data were analyzed with repeated measures analyses of variance and appropriate post-comparisons with Scheffé test for the experiments with repeated injection of drugs in escalating doses and for the time-course experiments. The criterion of significance was set at p Ͻ 0.05. All results were expressed as the mean Ϯ S.E.M.
Results
Peripheral Nociceptive Flexor Responses Produced by Nocistatin and ppN/OFQ 160 -187 (C-Peptide).
The i.pl. injection of nocistatin produced dose-dependent nociceptive flexor responses (Fig. 1A ). An i.pl. injection of nocistatin at a dose of 10 pmol induced a flexor response corresponding to a force of 5.3 Ϯ 0.2 g (mean Ϯ S.E.M.) in all mice used throughout experiments (n ϭ 40). The nociceptive dose of nocistatin showing 50% of maximal reflex (ED 50 ) was 33.9 Ϯ 9.1 fmol in the experiments for increasing doses of nocistatin (n ϭ 6). The ED 50 value of nocistatin was 100 to 1,000 times higher than those of N/OFQ (0.4 Ϯ 0.1 fmol, n ϭ 6) or its fragment, N/OFQ (13-17) (0.02 Ϯ 0.007 fmol, n ϭ 6). Similar nociception was also observed with C-peptide. The ED 50 value of C-peptide-induced nociception was 110.0 Ϯ 23.2 fmol (n ϭ 5). The wide dynamic ranges of nocistatin-or C-peptideinduced flexor responses suggest that this animal model would be readily amendable to pharmacological interventions and provide a very useful tool for the in vivo analysis of signaling of nociceptive responses by pain-producing substances.
Lack of Blockade Nocistatin-and C-Peptide-Induced Nociception by NOP Antagonist. Although nocistatin or C-peptide (i.pl.) induced dose-dependent nociceptive flexor responses in a range of 0.01 to 10 or to 1 pmol (i.pl.), respectively, in the ANF tests, these responses were not affected by J-113397, a nonpeptidic NOP antagonist (Ozaki et al., 2000; Ueda et al., 2000a ) at a dose of 10 pmol, which had been pretreated 20 min before administration of nocistatin or Cpeptide through another adjacent cannule (Fig. 1, B and C) . However, the N/OFQ (1 fmol, i.pl.)-induced response was completely abolished by this antagonist at a dose as low as 10 fmol (Fig. 1D) , as reported previously (Ueda et al., 2000a) . This finding is consistent with the previous report that the spinal response by nocistatin is retained in mice lacking the genomic NOP (Ahmadi et al., 2001) .
In Vivo Signal Transduction of Nocistatin-Induced Pronociceptive Responses. Nocistatin (i.pl.)-induced nociceptive responses were completely abolished by the i.pl. injection of 10 ng of pertussis toxin in between nocistatin challenges ( Fig. 2A) . The AS-ODN for G␣ s was pretreated to reduce its protein expression in sensory neurons. As shown in Fig. 2B , nocistatin-induced nociceptive responses were not affected, but the G␣ s expression in the dorsal root ganglion was markedly reduced by this pretreatment (Fig. 2C) . The nocistatin responses were markedly inhibited by 3 nmol of U-73122, a phospholipase C inhibitor (Fig. 2D ), but not by 3 nmol of U-73343, its inactive isomer (data not shown). In addition, these responses were also markedly blocked by 1 pmol of CP-99994, a substance P (neurokinin 1) receptor antagonist, as shown in Fig. 2E .
In Vivo Signal Transduction of C-Peptide-Induced Pronociceptive Responses. On the other hand, the Cpeptide (i.pl.)-induced pronociceptive responses were not affected by pertussis toxin (Fig. 3A) , whereas they were abolished by the pretreatment with AS-ODN for G␣ s , but not with MS-ODN (Fig. 3B) . The responses were abolished by KT-5720, a cyclic AMP-dependent protein kinase (PKA) inhibitor, but not by U-73122 nor calphostin C, a protein kinase C inhibitor (Fig. 3, C and D) , which effectively blocked acute morphine (i.pl.) analgesic tolerance .
Characterization of Nociceptive Fibers Stimulated by Nocistatin and C-Peptide. In neonatal capsaicintreated mice, which degenerates polymodal C-fibers (Inoue et al., 1999) , nocistatin (i.pl.)-induced nociceptive responses at doses of 0.01 to 10 pmol were markedly inhibited, as shown in Fig. 4A . The i.t. treatment with CP-99994 (1 nmol) 20 min before the ANF test also abolished the nocistatin responses (Fig. 4B) . However, the pretreatment with MK-801, an NMDA receptor antagonist (1 nmol i.t.) did not affect these responses (Fig. 4B) . The C-peptide-induced nociception was not affected by the neonatal pretreatment with capsaicin or by CP-99994 (i.t.), whereas it was completely abolished by MK-801 (i.t.), as shown in Fig. 4 , C and D. AS-ODN (i.t.) was injected on the 1st, 3rd, and 5th days. On the 6th day mice were used to assess the NST-induced nociception (B), and expression of G␣ s protein in dorsal root ganglion (C). Each point represents the mean Ϯ S.E.M. from separate six experiments. Other details are given in the legend to Fig. 1 .
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Discussion
Many precursor proteins produce several different biologically active peptides, which are contained in their sequences (Rehfeld et al., 1989) . A family of opioid peptides is a representative case (Noda et al., 1982) . All opioid peptides derived from their three distinct precursors have affinities to either of three distinct types of receptors (Goldstein, 1987) . However, all these receptors are coupled to pertussis toxin-sensitive G proteins (G i/o ) . N/OFQ has been discovered as the endogenous peptide ligand for opioid receptor-like G i/o -coupled NOP (Meunier et al., 1995; Reinscheid et al., 1995) . The amino acid sequence of N/OFQ is also similar to dynorphin A (1-17). All these facts suggest that opioid peptide precursors and prepro-N/OFQ might be derived from the same ancestor protein (Darland, 1998) . However, the present findings demonstrated that prepro-N/OFQ-derived peptides have distinct features in their cellular signalings.
We found four peptides derived from preproN/OFQ caused significant dose-dependent nociceptive flexor responses in the ANF test (Fig. 1A) . Because the responses caused by the third dose (1 fmol) of N/OFQ were equivalent to those by the initial dose (1 fmol) (Fig. 1, A and D) , the dose orderly effects likely result from increasing dose, but not repeated injection of algogenic substance. Similar discussion is also true with nocistatin and C-peptide (Figs. 1, A-C, 2B, 3B, and 4, A-D) . Because the nociceptive flexor responses evaluated by percentage of maximal reflex are constant upon repeated challenges and reproducible from mice to mice, we attenuated to characterize the in vivo signalings of pronociceptive actions of these peptides. Throughout a series of experiments using this test, we have proposed at least three different types of nociceptive fibers stimulated by various algogenics. The nociceptor type classification in these studies was defined by the pharmacological characteristics, such as susceptibility to neonatal capsaicin pretreatment, which is known to degenerates C-fibers (Inoue et al., 1999) , and to the i.t. injection of substance P (neurokinin 1) or glutamate (NMDA) receptor antagonists. In this paradigm, bradykinin, substance P, and histamine through G q/11 -coupled receptors or N/OFQ, kyotorphin, and morphine through G i/o -coupled receptors stimulate neonatal capsaicin-sensitive polymodal C fibers, which use substance P and neurokinin 1 receptor for primary afferent pain transmission in the spinal cord (we call it type I), whereas ATP and P2X 3 agonist through P2X 3 receptor stimulate the capsaicin-sensitive fibers, which use glutamate and NMDA receptor for the pain transmission (we call it type II). On the other hand, prostaglandin I 2 -agonist stimulates the capsaicin-insensitive fibers, which use glutamate and NMDA receptor for the pain transmission (we call it type III).
The type I and II fibers in our definition likely correspond to those defined by Snider and McMahon (1998) , with (class I) polymodal C-fiber containing substance P and possessing sensitivity to nerve growth factor, and (class II) polymodal C-fiber expressing P2X 3 -type ATP receptor and possessing sensitivity to glia-derived neurotrophic factor, although details on the similarity remain to be determined. The type III fibers in our studies, on the other hand, apparently differ from these two types of fibers in the point of insusceptibility to neonatal capsaicin. Recently, we have found that type I-responses disappeared, type II ones without changes, whereas prostaglandin I 2 agonist-induced type III ones markedly potentiated after the partial sciatic nerve injury (Rashid et al., 2003) . The potentiation of prostaglandin I 2 agonist-induced responses was abolished by local application with capsaicin cream, which desensitizes the nociceptor endings through capsaicin receptor (TRPV1). In addition to these, immunoreactive TRPV1 was newly expressed in N52-positive A-fiber neurons after the injury. Although more detailed studies to characterize type III fibers should be necessary, these results suggest that type III responses are likely through A-fibers and also have distinct characteristics from the other two types of algogenicinduced responses, particularly after the nerve injury. Using this system, here we attempted to characterize the in vivo signaling of nociceptive flexor responses induced by N/OFQ, nocistatin, and C-peptide. Nocistatin-induced responses were completely abolished by the i.pl. injection of 10 ng of pertussis toxin in between nocistatin challenges ( Fig.  2A) . The blockade was observed as early as 10 min after application of the pertussis toxin. Such a rapid blockade has also been observed in other cases with N/OFQ, kyotorphin, and morphine (Inoue et al., 1998; Ueda and Inoue 2000; Ono et al., 2002) . These findings strongly suggest that nocistatin stimulates an unidentified but putative G i/o -coupled receptor, as well as N/OFQ (Inoue et al., 1998) . For a comparison with N/OFQ (Inoue et al., 1998 ), various inhibitors were tested to clarify in vivo signaling of nocistatin responses. We found that this peptide shares common post-receptor mechanisms through G i/o , phospholipase C and substance P release from nociceptor endings with N/OFQ (Fig. 5) . Although nocistatin has been reported as an endogenous peptide to inhibit N/OFQ-induced allodynia and hyperalgesia (Okuda-Ashitaka et al., 1998; Okuda-Ashitaka and Ito, 2000) ; however, it remains to be determined what mechanisms are involved in the blockade of N/OFQ-actions by nocistatin. It might be possible that nocistatin counteracts the N/OFQ actions in vivo through different synaptic pathways. Details of the different in vivo pain-regulatory roles of both of these peptides need to be elucidated.
On the other hand, C-peptide was found to use different mechanisms from N/OFQ and nocistatin. The C-peptide-induced nociceptive responses were insensitive to J-113397 and pertussis toxin. The most striking evidence was that the responses were abolished by pretreatments with AS-ODN for G␣ s and KT-5720. It should be further noted that they were insensitive to neonatal pretreatment with capsaicin, but were blocked by the intrathecal injection of MK-801, but not of CP-99994 (Fig. 5 ). These characteristics are quite similar to the mechanisms for the nociceptive responses induced by prostaglandin I 2 agonist (Ueda et al., 2000b) , whose receptor (IP receptor) is coupled to G s (Namba et al., 1994) through type III nociceptive fibers (Inoue et al., 2003a; Rashid et al., 2003) .
In a previous study, we reported that N/OFQ (13-17), a fragment peptide of N/OFQ, also induced nociceptive responses in ANF tests (Inoue et al., 2001) , with its potency being 100 times higher than N/OFQ. The in vivo signaling of these actions through G i/o and phospholipase C mechanisms is identical to those with N/OFQ and nocistatin. However, it remains to be seen whether these three peptides have distinct roles in pain regulation. In preliminary studies, they did not show significant stimulatory actions on [
35 S]guanosine 5Ј-O-(3-thio)triphosphate binding in the membrane preparations from dorsal root ganglion, whereas only N/OFQ did in a preparation from spinal cord. These observations may possibly be explained by a lower abundance in the expression of corresponding receptors in dorsal root ganglion, or by their selective translation in nerve endings. The latter possibility may be related to a report that Eph A2 receptor is selectively translated in nerve endings, but not in somatic regions (Brittis et al., 2002) .
In conclusion, the present study suggests that nocistatin and C-peptide as well as N/OFQ and N/OFQ (13-17), derived from the same prohormone, induced nociceptive flexor responses in ANF tests. It is also suggested that nocistatin, N/OFQ, and N/OFQ (13-17) share common signaling through G i/o , phospholipase C and substance P release from capsaicinsensitive type I C-fibers, whereas C-peptide uses the mechanisms through G s and PKA in capsaicin-insensitive type III fibers. 
